يعرض 1 - 20 نتائج من 33 نتيجة بحث عن '"B. Zurawski"', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1
    41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)

    المؤلفون: H. Borghaei, D. Balli, L. Paz-Ares, M. Reck, S.S. Ramalingam, J.R. Brahmer, T-E. Ciuleanu, A. Pluzanski, J-S. Lee, J. Gainor, M. Schenker, A. Schoenfeld, R. Bernabe Caro, N. Ready, K.H. Lee, B. Zurawski, C. Audigier-Valette, V. Baxi, W. Geese, K.J. O’Byrne

    المصدر: Journal of Thoracic Oncology. 18:S64-S65

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::721c6319fc853766964d5fc594abb609
    https://doi.org/10.1016/s1556-0864(23)00295-2

    View record in OpenAIRE

    أضف إلى المفضلة
  2. 2
    LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

    المؤلفون: T.K. Choueiri, T.B. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, M. Maruzzo, A. Suarez Zaizar, L.E. Fein, F.A. Barros Schutz, D.Y.C. Heng, F. Wang, F. Mataveli, Y-L. Chang, M. van Kooten Losio, C. Suarez Rodriguez, R.J. Motzer

    المصدر: Annals of Oncology. 33:S1430-S1431

    مصطلحات موضوعية: Oncology, Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b1c280907cf84f449030af4c0c87eaf7
    https://doi.org/10.1016/j.annonc.2022.08.070

    View record in OpenAIRE

    أضف إلى المفضلة
  3. 3
    First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    المؤلفون: A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, Luis Paz-Ares, Yuichiro Ohe, Hossein Borghaei, Kenneth J. O'Byrne, L. Lupinacci, Phuong Tran, Jong Seok Lee, Makoto Nishio, Kynan Feeney, Masayuki Takeda, Enric Carcereny, Adam Pluzanski, F. E. Nathan, Carlos Gallardo, Judith Bushong, Keunchil Park, B. Zurawski, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Gregory A. Otterson

    المساهمون: Bristol-Myers Squibb, Ono Pharmaceutical

    المصدر: Journal of Thoracic Oncology
    r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
    instname

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Adult, medicine.medical_specialty, Lung Neoplasms, Immunotherapy, First line, medicine.medical_treatment, Ipilimumab, PD-1 checkpoint inhibitor, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Chemotherapy, CTLA-4, First-line, business.industry, Confidence interval, Discontinuation, Nivolumab, Metastatic non–small cell lung cancer, Open label, Neoplasm Recurrence, Local, business, medicine.drug

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f7125153a7a538998a341b2f60e83e
    http://hdl.handle.net/10261/305831

    View record in OpenAIRE

    أضف إلى المفضلة
  4. 4
    Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

    المؤلفون: J.A. Ledermann, B. Zurawski, F. Raspagliesi, U. De Giorgi, J. Arranz Arija, M. Romeo Marin, A. Lisyanskaya, R.L. Póka, J. Markowska, C. Cebotaru, A. Casado Herraez, N. Colombo, E. Kutarska, M. Hall, A. Jacobs, I. Ahrens-Fath, H. Baumeister, A. Zurlo, J. Sehouli

    المساهمون: Ledermann, J, Zurawski, B, Raspagliesi, F, De Giorgi, U, Arranz Arija, J, Romeo Marin, M, Lisyanskaya, A, Póka, R, Markowska, J, Cebotaru, C, Casado Herraez, A, Colombo, N, Kutarska, E, Hall, M, Jacobs, A, Ahrens-Fath, I, Baumeister, H, Zurlo, A, Sehouli, J

    المصدر: ESMO Open

    مصطلحات موضوعية: Ovarian Neoplasms, Cancer Research, palliative care, TA-MUC 1, Mucin-1, Carcinoma, Ovarian Epithelial, Antibodies, Monoclonal, Humanized, Maintenance Chemotherapy, Antineoplastic Agents, Immunological, ovarian cancer, Oncology, Double-Blind Method, Quality of Life, Humans, Female, gatipotuzumab, Neoplasm Recurrence, Local, ADCC, Original Research

    وصف الملف: ELETTRONICO

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21dafef0b1578b36428d940a42d27a97
    https://hdl.handle.net/10281/403233

    View record in OpenAIRE

    أضف إلى المفضلة
  5. 5
    First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

    المؤلفون: X. Zhang, Michael Schenker, Shunyuan Lu, Arnaud Scherpereel, Maurice Pérol, A. Lingua, Manuel Cobo, S. Marimuthu, Tudor-Eliade Ciuleanu, Arteid Memaj, Eduardo Richardet, O. Juan-Vidal, F. Reyes, David P. Carbone, B. Zurawski, A. Alexandru, Phuong Tran, Hiroshi Sakai, Jaafar Bennouna, Martin Reck, Enriqueta Felip, Thomas John, Juliana Janoski de Menezes, Pierre-Jean Souquet, C. Martin, Luis Paz-Ares, P. De Marchi

    المساهمون: German Center for Lung Research, Institutul oncologic Prof Dr Ion Chiricuta [Cluj-Napoca, Romania], Instituto de Investigación Biomédica [Malaga, Spain] (IBIMA), SF Nectarie Oncology Center [Craiova, Romania], Ambulatorium Chemioterapii [Bydgoszcz, Poland] (AC), Hospital Nossa Senhora Da Conceição [Porto Alegre, Brazil] (HNSDC), Instituto Oncológico De Córdoba [Córdoba, Argentina] (IODC), Immunogenic Cell Death and Mesothelioma Therapy (CRCINA-ÉQUIPE 4), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Vall d'Hebron University Hospital [Barcelona], Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe, Oncology Institute of Bucharest Professor Doctor Alexandru Trestioreanu [Bucharest, Romania] (OIB), Saitama Cancer Center [Saitama, Japan] (S2C), Instituto Medico Rio Cuarto SA [Córdoba, Argentina] (IMRC), Fundacion Arturo Lopez Perez [Santiago, Metropolitana, Chile] (FALP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Barretos Cancer Hospital [São Paulo, Brazil] (BCH), Instituto Alexander Fleming [Buenos Aires, Argentina] (IAF), Centre Léon Bérard [Lyon], Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Shanghai Jiaotong University, Hospital Universitario 12 de Octubre [Madrid], Ohio State University [Columbus] (OSU), Bristol-Myers Squibb [Princeton], Austin Hospital [Melbourne], Austin Health, Bernardo, Elizabeth, Institut Català de la Salut, [Reck M] Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. [Ciuleanu TE] Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania. [Cobo M] Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Schenker M] Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania. [Zurawski B] Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland. [Menezes J] Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: ESMO Open
    ESMO Open, 2021, 6 (5), pp.100273. ⟨10.1016/j.esmoop.2021.100273⟩
    Scientia
    Esmo Open
    r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
    instname

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Other subheadings::Other subheadings::/drug therapy [Other subheadings], NSCLC, Quimioteràpia combinada, nivolumab, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Carcinoma, Non-Small-Cell Lung, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, first-line, ipilimumab, Lung cancer, Adverse effect, NSCLC, dual immunotherapy, first-line, ipilimumab, nivolumab, Original Research, Chemotherapy, business.industry, Hazard ratio, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], medicine.disease, Confidence interval, Discontinuation, Nivolumab, dual immunotherapy, Neoplasm Recurrence, Local, business, Corrigendum, Pulmons - Càncer - Tractament, medicine.drug

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9589559f779d6c7e2f62cb2eac8678f
    https://www.hal.inserm.fr/inserm-03540859/document

    View record in OpenAIRE

    أضف إلى المفضلة
  6. 6
    Nivolumab + ipilimumab (NIVO + IPI) adjuvant versus placebo dans le carcinome rénal localisé à haut risque de récidive après néphrectomie : résultats de l’étude de phase 3 randomisée Checkmate 914 (CM914)

    المؤلفون: P. Barthélémy, R. Motzer, P. Russo, V. Grünwald, Y. Tomita, B. Zurawski, O. Parikh, S. Buti, J. Goh, D. Ye, A. Lingua, J. Lattouf, B. Escudier, S. George, B. Shuch, B. Simsek, J. Spiridigliozzi, A. Chudnovsky, A. Bex

    المصدر: Progrès en Urologie - FMC. 32:S88

    مصطلحات موضوعية: Urology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5fbbc76b1450f7372f79abf9d9a68201
    https://doi.org/10.1016/j.fpurol.2022.07.100

    View record in OpenAIRE

    أضف إلى المفضلة
  7. 7
    LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

    المؤلفون: R.J. Motzer, P. Russo, V. Gruenwald, Y. Tomita, B. Zurawski, O.A. Parikh, S. Buti, P. Barthelemy, J.C.H. Goh, D. Ye, A. Lingua, J-B. Lattouf, B. Escudier, S. George, null B. Shuch, B. Simsek, J. Spiridigliozzi, A. Chudnovsky, A. Bex

    المصدر: Annals of Oncology. 33:S1430

    مصطلحات موضوعية: Oncology, Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8e477c73702cb547e5b773bfdbd72cdd
    https://doi.org/10.1016/j.annonc.2022.08.069

    View record in OpenAIRE

    أضف إلى المفضلة
  8. 8
    1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA

    المؤلفون: T. John, T-E. Ciuleanu, M. Cobo Dols, M. Schenker, B. Zurawski, J. Menezes, E.A. Richardet, J. Bennouna, Y. Cheng, E. Felip, O.J. Juan Vidal, A. Alexandru, L. Paz-Ares, S. Lu, M. Reck, N. Hu, X. Zhang, D.J. Grootendorst, L. Eccles, D.P. Carbone

    المصدر: Annals of Oncology. 33:S1034

    مصطلحات موضوعية: Oncology, Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9e8e1523e7fb86ecebffaac7422a2813
    https://doi.org/10.1016/j.annonc.2022.07.1175

    View record in OpenAIRE

    أضف إلى المفضلة
  9. 9
    First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA

    المؤلفون: Phuong Tran, Aurella Alexandru, S. Marimuthu, Tudor-Eliade Ciuleanu, Hiroshi Sakai, Manuel Cobo, Luis Paz-Ares, Michael Schenker, Jaafar Bennouna, Arnaud Scherpereel, Arteid Memaj, Enriqueta Felip, O. Juan-Vidal, David P. Carbone, B. Zurawski, Thomas John, Eduardo Richardet, Juliana Janoski de Menezes, Shun Lu, Martin Reck

    المساهمون: German Center for Lung Research, Institutul oncologic Prof Dr Ion Chiricuta [Cluj-Napoca, Romania], Instituto de Investigación Biomédica [Malaga, Spain] (IBIMA), SF Nectarie Oncology Center [Craiova, Romania], Ambulatorium Chemioterapii [Bydgoszcz, Poland] (AC), Hospital Nossa Senhora Da Conceição [Porto Alegre, Brazil] (HNSDC), Instituto Oncológico De Córdoba [Córdoba, Argentina] (IODC), Immunogenic Cell Death and Mesothelioma Therapy (CRCINA-ÉQUIPE 4), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Vall d'Hebron University Hospital [Barcelona], Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe, Oncology Institute of Bucharest Professor Doctor Alexandru Trestioreanu [Bucharest, Romania] (OIB), Saitama Cancer Center [Saitama, Japan] (S2C), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Shanghai Jiaotong University, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Ohio State University [Columbus] (OSU), Bristol-Myers Squibb [Princeton], Bristol Myers Squibb [Springfield, PA, USA] (BMS), Austin Hospital [Melbourne], Austin Health, Bernardo, Elizabeth

    المصدر: Journal of Clinical Oncology
    Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.9000-9000. ⟨10.1200/JCO.2021.39.15_suppl.9000⟩

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, First line, Checkmate, non-small cell lung cancer (NSCLC), Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, medicine.disease, stomatognathic diseases, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, hemic and lymphatic diseases, medicine, Overall survival, In patient, Nivolumab, business, neoplasms, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4b2800a2aa277d299a7b3e6fbe4f791
    https://www.hal.inserm.fr/inserm-03540833

    View record in OpenAIRE

    أضف إلى المفضلة
  10. 10
    First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

    المؤلفون: Pierre-Jean Souquet, David P. Carbone, Michael Schenker, Shun Lu, S. Meadows-Shropshire, A. Alexandru, Pamela Salman, Hiroshi Sakai, Jaafar Bennouna, Maurice Pérol, Enriqueta Felip, Alejo Lingua, J. Yan, Juliana Janoski de Menezes, B. Zurawski, Martin Reck, Arnaud Scherpereel, C. Martin, Eduardo Richardet, Abderrahim Oukessou, Tudor-Eliade Ciuleanu, Manuel Cobo, O. Juan-Vidal, Pedro Rafael Martins De Marchi, Thomas John, Luis Paz-Ares, Shruti Agrawal

    المساهمون: Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), The Oncology Institute 'Prof. Dr. Ion Chiricuţă' [Cluj-Napoca, Romania] (TOI), Instituto de Investigación Biomédica [Malaga, Spain] (IBIMA), SF Nectarie Oncology Center [Craiova, Romania], Ambulatorium Chemioterapii [Bydgoszcz, Poland] (AC), Hospital Nossa Senhora Da Conceição [Porto Alegre, Brazil] (HNSDC), Instituto Oncológico De Córdoba [Córdoba, Argentina] (IODC), Immunogenic Cell Death and Mesothelioma Therapy (CRCINA-ÉQUIPE 4), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre hospitalier universitaire de Nantes (CHU Nantes), Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Hospital Universitario La Fe [Valencia, Spain] (HU), Oncology Institute of Bucharest Professor Doctor Alexandru Trestioreanu [Bucharest, Romania] (OIB), Saitama Cancer Center [Saitama, Japan] (S2C), Instituto Medico Rio Cuarto SA [Córdoba, Argentina] (IMRC), Fundacion Arturo Lopez Perez [Santiago, Metropolitana, Chile] (FALP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Barretos Cancer Hospital [São Paulo, Brazil], Instituto Alexander Fleming [Buenos Aires, Argentina] (IAF), Centre Léon Bérard [Lyon], Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University of Lille, CHU Lille, Shanghai Jiao Tong University [Shanghai], Austin Hospital [Melbourne], Austin Health, Ohio State University [Columbus] (OSU), Bristol-Myers Squibb [Princeton], German Center for Lung Research, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe, Bernardo, Elizabeth

    المصدر: LANCET ONCOLOGY
    r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
    instname
    Lancet
    Lancet, Elsevier, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩
    The Lancet
    The Lancet, 2021, 22 (2), pp.198-211. ⟨10.1016/S1470-2045(20)30641-0⟩

    مصطلحات موضوعية: Male, medicine.medical_specialty, Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neutropenia, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Aged, Neoplasm Staging, business.industry, Hazard ratio, Middle Aged, medicine.disease, Interim analysis, 3. Good health, respiratory tract diseases, Regimen, Nivolumab, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Febrile neutropenia, medicine.drug

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa94d86fd54759cc80a6aa8c6a4c99f6
    https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13780

    View record in OpenAIRE

    أضف إلى المفضلة
  11. 11
    First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

    المؤلفون: Helena Linardou, Xiaowu Sun, Krysztof Lesniewski-Kmak, Michael Schenker, Samreen Ahmed, Kenneth J. O'Byrne, Konstantinos N. Syrigos, Martin Reck, Alejandro Moreno-Koehler, Fiona Taylor, Makoto Nishio, John R. Penrod, Yong Yuan, Clarisse Audigier-Valette, Jong Seok Lee, Tudor Ciuleanu, Emmanuel de la Mora Jimenez, F. E. Nathan, Istvan Albert, B. Zurawski, Pamela Salman, Gregory A. Otterson, Steven I. Blum

    المصدر: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(4)

    مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Visual analogue scale, Population, Ipilimumab, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Patient Reported Outcome Measures, education, Lung cancer, education.field_of_study, business.industry, Hazard ratio, Repeated measures design, medicine.disease, Confidence interval, 030104 developmental biology, Nivolumab, 030220 oncology & carcinogenesis, Quality of Life, Neoplasm Recurrence, Local, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae0341587342c02a4c9bbdd1dba102b
    https://pubmed.ncbi.nlm.nih.gov/33781441

    View record in OpenAIRE

    أضف إلى المفضلة
  12. 12
    Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles d’un doublet de chimiothérapie à base de sels de platine (CT) vs 4 cycles de chimiothérapie en 1ère ligne (1L) de traitement du cancer bronchique non à petites cellules (CBNPC) au stade avancé : données du suivi à 2 ans de l’étude CheckMate 9LA (CM 9LA)

    المؤلفون: A. Scherpereel, M. Reck, T.E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, S. Lu, L. Paz-Ares, D.P. Carbone, A. Memaj, S. Marimuthu, P. Tran, T. John

    المصدر: Revue des Maladies Respiratoires Actualités. 14:198

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2949564f2efa861d412f763651a9d43c
    https://doi.org/10.1016/j.rmra.2021.11.348

    View record in OpenAIRE

    أضف إلى المفضلة
  13. 13
    Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’

    المؤلفون: M. Reck, T.-E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P.-J. Souquet, P. De Marchi, C. Martin, M. Pérol, A. Scherpereel, S. Lu, L. Paz-Ares, D.P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, T. John

    المصدر: ESMO Open. 6:100345

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::eb899283d9b2e0812ecb3e57932daed1
    https://doi.org/10.1016/j.esmoop.2021.100345

    View record in OpenAIRE

    أضف إلى المفضلة
  14. 14
    98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

    المؤلفون: Arnaud Scherpereel, Shunyuan Lu, T-E. Ciuleanu, Luis Paz-Ares, S. Meadows-Shropshire, David P. Carbone, B. Zurawski, Jaafar Bennouna, Shruti Agrawal, Thomas John, Enriqueta Felip, M. Cobo, J. Menezes, M. Schenker, O. Juan-Vidal, D. Balli, Eduardo Richardet, A. Alexandru, Hiroshi Sakai, Martin Reck

    المصدر: Journal of Thoracic Oncology. 16:S750-S751

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, First line, medicine.medical_treatment, Checkmate, Ipilimumab, medicine.disease, Internal medicine, medicine, Non small cell, Nivolumab, business, Lung cancer, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8a40c187bbfba499d46ae4105b396a08
    https://doi.org/10.1016/s1556-0864(21)01940-7

    View record in OpenAIRE

    أضف إلى المفضلة
  15. 15
    OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

    المؤلفون: D.J. Grootendorst, M. Schenker, Jaafar Bennouna, Enriqueta Felip, E. De La Mora Jimenez, Shunyuan Lu, Phuong Tran, M. Cobo, X. Zhang, O. Juan-Vidal, David P. Carbone, Thomas John, Martin Reck, B. Zurawski, J. Menezes, Luis Paz-Ares, Tudor-Eliade Ciuleanu, A. Alexandru, Hiroshi Sakai, N. Hu, Eduardo Richardet

    المصدر: Journal of Thoracic Oncology. 16:S862

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, First line, Checkmate, Ipilimumab, Internal medicine, medicine, In patient, Nivolumab, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5684b06d841ee18d99365b037f754818
    https://doi.org/10.1016/j.jtho.2021.08.061

    View record in OpenAIRE

    أضف إلى المفضلة
  16. 16
    67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1

    المؤلفون: P. Sun, Pamela Salman, S.-B. Kim, M. Schenker, Helena Linardou, E. De La Mora Jimenez, Fabrice Barlesi, Clarisse Audigier-Valette, Ang Li, Kynan Feeney, Matthew D. Hellmann, Istvan Albert, T-E. Ciuleanu, Gregory A. Otterson, Julie R. Brahmer, Samreen Ahmed, Krzysztof Lesniewski-Kmak, Norbert Frickhofen, B. Zurawski

    المصدر: Annals of Oncology. 31:S1444-S1445

    مصطلحات موضوعية: Oncology, First line treatment, medicine.medical_specialty, business.industry, Internal medicine, medicine, Checkmate, Ipilimumab, Hematology, Nivolumab, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b9f16506efdcbac73e03702bd8cb9d0f
    https://doi.org/10.1016/j.annonc.2020.10.555

    View record in OpenAIRE

    أضف إلى المفضلة
  17. 17
    LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

    المؤلفون: M. Schenker, Jaafar Bennouna, Luis Paz-Ares, J. Menezes, M. Cobo, T-E. Ciuleanu, Shuliang Lu, Yong Yuan, David P. Carbone, Ying Cheng, J. Yan, B. Padilla, Thomas John, B. Zurawski, A. Moisei, Eduardo Richardet, Steven I. Blum, X. Sun, Martin Reck

    المصدر: Annals of Oncology. 31:S1187-S1188

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, business.industry, First line, medicine.medical_treatment, Checkmate, non-small cell lung cancer (NSCLC), Ipilimumab, Hematology, medicine.disease, Internal medicine, Medicine, Nivolumab, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ddb993ac7569f78be09ab7f8330ba33f
    https://doi.org/10.1016/j.annonc.2020.08.2292

    View record in OpenAIRE

    أضف إلى المفضلة
  18. 18
    1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study

    المؤلفون: G. Ursol, I. Demedts, M. Tsuboi, Alexander Luft, B. Zurawski, E. Eigendorff, Marina Chiara Garassino, Heather A. Wakelee, H. Berard, J. Yang, Terufumi Kato, E. Levchenko, K. Makarious, Steven M. Keller

    المصدر: Annals of Oncology. 31:S801-S802

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Locally advanced, chemistry.chemical_element, Hematology, Pembrolizumab, Perioperative, medicine.disease, chemistry, Internal medicine, medicine, Non small cell, Lung cancer, business, Platinum

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3bb85aea3e56b8f8380cb6bad50f8b4f
    https://doi.org/10.1016/j.annonc.2020.08.1437

    View record in OpenAIRE

    أضف إلى المفضلة
  19. 19
    OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

    المؤلفون: J. Yan, S. Meadows-Shropshire, David P. Carbone, Manuel Cobo Dols, Tudor-Eliade Ciuleanu, Arnaud Scherpereel, M. Schenker, A. Alexandru, Hiroshi Sakai, Eduardo Richardet, Shunyuan Lu, Luis Paz-Ares, Thomas John, Martin Reck, B. Zurawski, J. Menezes, Jaafar Bennouna, Enriqueta Felip, Oscar Juan Vidal

    المصدر: Journal of Thoracic Oncology. 16:S2

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Chemotherapy, business.industry, First line, medicine.medical_treatment, Checkmate, Ipilimumab, Recurrent Non-Small Cell Lung Cancer, Internal medicine, Medicine, Nivolumab, Stage iv, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::622e62e3084b64f73edcc8d26a6a5d18
    https://doi.org/10.1016/j.jtho.2020.10.022

    View record in OpenAIRE

    أضف إلى المفضلة
  20. 20
    Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles d’un doublet de chimiothérapie à base de sels de platine (CT) vs 4 cycles de chimiothérapie en 1re ligne (1L) de traitement du cancer bronchique non à petites cellules (CBNPC) stade avancé : CheckMate 9LA (CM 9LA)

    المؤلفون: Tudor-Eliade Ciuleanu, E. Felip, Martin Reck, J. Yan, Shunyuan Lu, M. Schenker, David P. Carbone, Eduardo Richardet, J. Menezes, Luis Paz-Ares, J. Bennouna, S. Meadows-Shropshire, Arnaud Scherpereel, Thomas John, A. Alexandru, Manuel Cobo Dols, H. Sakai, B. Zurawski, O.J. Vidal

    المصدر: Revue des Maladies Respiratoires Actualités. 13:123

    مصطلحات موضوعية: Pulmonary and Respiratory Medicine

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e78b52404409fa5d542b059c1e6bc9c6
    https://doi.org/10.1016/j.rmra.2020.11.252

    View record in OpenAIRE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء